Genemedicine Co., Ltd.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Genemedicine Co., Ltd..The latest application filed is for "antitumor immunity enhancing composition containing adenovirus simultaneously expressing il-12 and shvegf".

Company Profile

12.14.17

Genemedicine Co., Ltd. - Seoul KR
GENEMEDICINE CO., LTD. - N/A
GENEMEDICINE CO., LTD. - KR KR
GENEMEDICINE CO., LTD. - Seongdong-gu Seoul KR
GENEMEDICINE CO., LTD - Seongdong-gu Seoul KR
Genemedicine CO., LTD. - Seongdong-gu KR
GENEMEDICINE CO., LTD. -

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Antitumor Immunity Enhancing Composition Containing Adenovirus Simultaneously Expressing Il-12 And Shvegf App 20220233718 - YUN; Chae Ok ; et al.	2022-07-28
Anticancer composition comprising tumor-specific oncolytic adenovirus and immune checkpoint inhibitor Grant 11,364,272 - Yun , et al. June 21, 2	2022-06-21
Ph-sensitive And Bioreducible Polymer-virus Complex For Cancer Treatment App 20220090025 - YUN; Chae Ok ; et al.	2022-03-24
Adenovirus complex for gene delivery and gene iherapy Grant 11,235,072 - Yun , et al. February 1, 2	2022-02-01
Anti-tumor Composition App 20210386806 - YUN; Chae Ok ; et al.	2021-12-16
Ph-sensitive and bioreducible polymer-virus complex for cancer treatment Grant 11,174,465 - Yun , et al. November 16, 2	2021-11-16
Virus-PCION complex having enhanced antitumor effect by using electromagnetic field Grant 11,000,590 - Yun , et al. May 11, 2	2021-05-11
Recombinant Adenoviruses And Stem Cells Comprising Same App 20210069253 - YUN; Chae Ok ; et al.	2021-03-11
Cell Sheet For Gene Delivery App 20210054332 - YUN; Chae Ok ; et al.	2021-02-25
Composition for intracellular delivery containing adenovirus protein VI-derived peptide and anticancer pharmaceutical composition containing same Grant 10,722,587 - Yun	2020-07-28
Anticancer Composition Comprising Tumor-specific Oncolytic Adenovirus And Immune Checkpoint Inhibitor App 20190388488 - YUN; Chae Ok ; et al.	2019-12-26
Anticancer Composition Comprising Recombinant Adenovirus Expressing Degradation Factor For Extracellular Matrix App 20190358277 - YUN; Chae Ok ; et al.	2019-11-28
Gene Delivery System Containing Relaxin Gene And Pharmaceutical Composition Using Relaxin App 20190323035 - YUN; Chae-Ok ; et al.	2019-10-24
Decorin gene delivery system and cancer treatment Grant 10,046,067 - Yun , et al. August 14, 2	2018-08-14
Anti-cancer compositions containing Wnt decoy receptor Grant 9,920,099 - Yun , et al. March 20, 2	2018-03-20
Anti-cancer Compositions Containing Wnt Decoy Receptor App 20170275340 - YUN; Chae Ok ; et al.	2017-09-28
Gene delivery system having enhanced tumor-specific expression, and recombinant gene expression regulating sequence Grant 9,689,000 - Yun , et al. June 27, 2	2017-06-27
Anti-cancer compositions containing WNT decoy receptor Grant 9,657,069 - Yun , et al. May 23, 2	2017-05-23
Decorin Gene Delivery System And Cancer Treatment App 20170080106 - YUN; Chae-Ok ; et al.	2017-03-23
Decorin gene delivery system and cancer treatment Grant 9,468,690 - Yun , et al. October 18, 2	2016-10-18

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.